Neuropathy Progression in Variant Transthyretin Amyloidosis: Comparison Between TTR Stabilizers and Gene Silencer Therapies
Muscle & Nerve · 2026-12 · 74 (6) · 1546-1553
DOI: 10.1002/mus.70406 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Muscle & Nerve, online erschienen am 15.09.2026. Verfasst von Catarina Falcão de Campos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hospital Santa Maria, Lisbon, Portugal. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Prealbumin, Benzoxazoles, Polyneuropathies. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
Introduction/Aims Transthyretin ( TTR ) stabilizers and gene‐silencing therapies are approved for hereditary transthyretin‐mediated amyloidosis with polyneuropathy ( ATTRv ‐ PN ), but data from clinical practice in patients who transition between therapies due to disease progression remains limited. The primary aim of this study is to evaluate the effectiveness of patisiran in ATTRv ‐ PN patients who progressed despite prior treatment with tafamidis 20 mg.
Methods
We conducted a retrospective multicenter observational study including patients with ATTRV30M (p.V50M) with polyneuropathy who were initially treated with tafamidis 20 mg and subsequently switched to patisiran due to documented neuropathy progression. Patients had at least 12 months of follow‐up under each treatment. Neuropathy progression was assessed using the Neuropathy Impairment Score (NIS), neurophysiological composite scores, nutritional status, serum biomarkers, and patient‐reported outcomes.
Results
Thirty‐two patients (mean age 52 ± 14 years; mean disease onset 43 ± 23.5 years) were included. Median disease duration before treatment initiation was 1.8 ± 1.9 years. The mean duration of tafamidis and patisiran treatment was 4.5 ± 2.8 and 2.5 ± 2.3 years, respectively. The annual increase in NIS was significantly lower during patisiran treatment than during tafamidis (0.7 ± 3.9 vs. 3.9 ± 4.7; p = 0.004). Decline in neurophysiological parameters slowed after switching.
Discussion
In this cohort, patisiran attenuated neuropathy progression in patients who had deteriorated despite tafamidis. These findings highlight the importance of ongoing clinical monitoring to guide timely treatment optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Hospital Santa Maria, Lisbon, Portugal.
- Centro de Estudos Egas Moniz, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
- Servicio de Medicina Interna, Hospital Universitario Son Llatzer, Instituto de Investigación Sanitaria Illes Balears, Palma, Spain.
ORCID-Profile: Catarina Falcão de Campos, Isabel de Castro, José Castro, Juan Gonzalez Moreno, Isabel Conceição
Zitieren
APA
Falcão de Campos, C., de Castro, I., Castro, J., Lopez, I. L., Moreno, J. G., & Conceição, I. (2026). Neuropathy Progression in Variant Transthyretin Amyloidosis: Comparison Between TTR Stabilizers and Gene Silencer Therapies. Muscle & Nerve, 74(6), 1546-1553. https://doi.org/10.1002/mus.70406
Vancouver
Falcão de Campos C, de Castro I, Castro J, Lopez IL, Moreno JG, Conceição I. Neuropathy Progression in Variant Transthyretin Amyloidosis: Comparison Between TTR Stabilizers and Gene Silencer Therapies. Muscle & Nerve. 2026;74(6):1546-1553. doi:10.1002/mus.70406
BibTeX
@article{FalcodeCampos2026,
author = {Falcão de Campos, Catarina and de Castro, Isabel and Castro, José and Lopez, Inês Losada and Moreno, Juan Gonzalez and Conceição, Isabel},
title = {Neuropathy Progression in Variant Transthyretin Amyloidosis: Comparison Between TTR Stabilizers and Gene Silencer Therapies},
journal = {Muscle & Nerve},
year = {2026},
volume = {74},
number = {6},
pages = {1546--1553},
doi = {10.1002/mus.70406}
}
EUVIMED